Citations

Clear

10 citation(s) found for "Shah, Parth".

Epidemiology, survival disparities, and future incidence projections of small intestine neuroendocrine carcinoma in the United States: A population-based SEER analysis.
Shah, P.S., Mal, Madho, TUMMALA, NAYANIKA, Nimmagadda, Rithish , Keswani, Shiwani, Jawed, Inshal, Gundakaram, Samhitha, Shah, Vedant , Rawal, Shalin, Nisha, Fnu, Shah, Parth Jay, Maroules, Michael, Nookala, Vinod, Shah, Nandan, Shah, Parjanya, Jawed, Inshal , Gundakaram, Samhitha , Kumar, Love

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16322 Get It

e16322 Background: Small intestine neuroendocrine carcinoma (NEC) is a rare, aggressive malignancy comprising less than 0.1% of gastrointestinal cancers. Population-level data remain limited, restricting understanding of long-term survival patterns, demographic disparities, and evolving disease burden. We evaluated survival outcomes, demographic predictors, and incidence trends of small intestine NEC in the United States. Methods: We conducted a retrospective population-based cohort study using SEER Research Data (17 registries, November 2024 submission). Patients diagnosed with malignant small intestine NEC (ICD-O-3 morphology code 9.3.3.1.2) between 2000 and 2022 were identified using SEER*Stat (v9.0.4.2). Variables including age group, sex, race, year of diagnosis, survival time, and vital status were analyzed in R (v4.5.1). Overall survival (OS) was estimated using Kaplan–Meier methods and compared using log-rank testing. Cox proportional hazards models identified independent predictors of OS. Annual case counts were modeled using time-series forecasting to project future incidence. Results: A total of 506 patients were included. Estimated OS was 94.4% (95% CI 92.4–96.4) at 1 year, 88.1% (85.3–91.0) at 3 years, and 82.4% (79.0–85.9) at 5 years, with a subset demonstrating survival beyond 15 years. Increasing age was associated with worse survival (log-rank p = 0.058). Significant racial differences in OS were observed (log-rank p < 0.0001). In multivariable analysis, race remained independently associated with OS. Incidence forecasting projected a modest increase in annual case burden over the next decade. Conclusions: Small intestine NEC demonstrates heterogeneous survival outcomes, significant demographic disparities, and projected growth in disease burden. These findings highlight the need for improved risk stratification, equitable access to care, and integration of molecular and treatment-level data to optimize management of this rare malignancy
Risk-adapted step-up local therapy for malignant portal vein tumor thrombus from hepatic metastases: A real-world study of microwave ablation with and without iodine-125 seed implantation.
Pham, Hoang Tran , Chun, Li, Bao, Weidong, Tian, Shichao, Zhao, Qingsong, Zhang, Mingyi , Yang, Z Y, Alba, Margarita De, Dong, Zhongyi , Parker, Jefferson , Morecroft, Renee, Elalfy, Aya, COTTLE, CHASEN, Ingram, Demarcus, Abdel-Hakeem, Ahmed, Bains, Shifali, Patel, Parth, Ali, Muhammad, Yang, Vivienne , Pham, Hoang Tran, Morecroft, Renée , Elalfy, Aya, Patel, Parth, Hartzell, Shannon

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4235-4235

10.1200/jco.2026.44.16_suppl.4235 Get It

4235 Background: Malignant portal vein tumor thrombus (PVTT) arising from hepatic metastases is associated with poor prognosis, rapid hepatic decompensation, and limited effective local treatment options despite systemic therapy. In real-world practice, local treatment intensity is frequently adapted to disease burden and treatment response. We evaluated outcomes of a risk-adapted, step-up local treatment strategy using microwave ablation (MWA) alone or in combination with iodine-125 (I-125) seed implantation for patients with malignant PVTT. Methods: We retrospectively reviewed patients with hepatic metastases treated with MWA with or without I-125 seed implantation between 2023 and July 2025. In clinical practice, MWA alone was preferentially used for patients with relatively limited disease burden, while MWA plus I-125 was employed as an escalation strategy for patients with more advanced PVTT or disease progression following MWA alone. The primary endpoint was PVTT-directed local outcome, defined as portal vein patency and/or local control of tumor thrombus on follow-up imaging. Secondary endpoints included progression-free survival (PFS), overall survival (OS), hepatic function changes, and treatment-related toxicity. Survival analyses were considered exploratory. Results: A total of 73 patients were included, of whom 50 were treated with MWA alone and 23 with MWA plus I-125 seed implantation. Patients receiving MWA plus I-125 demonstrated more advanced disease characteristics, including universal presence of PVTT and higher disease stage, consistent with treatment escalation by disease severity. Among patients with PVTT, MWA plus I-125 achieved portal vein patency and/or local control in 65% at first follow-up imaging. Treatment-related toxicities were manageable, with no unexpected grade ≥3 adverse events attributable to I-125 implantation. Median PFS was 11.5 months in patients treated with MWA alone and 9.9 months in patients treated with MWA plus I-125, consistent with greater baseline disease burden in the latter group. Conclusions: MWA alone and MWA plus I-125 function as complementary components of a risk-adapted, step-up local treatment strategy for malignant PVTT from hepatic metastases. Escalation to MWA plus I-125 appears feasible in patients with advanced or refractory PVTT and demonstrates a potential signal for improved PVTT-directed local control and portal vein patency. Prospective studies focused on PVTT-specific endpoints are warranted.
Abstract 271: Bradyarrhythmia Associated With Remdesivir And Covid-19 Pneumonia: A Pharmacovigilance Analysis:
Pandya, Krutarth K , Shah, Parth Rajeshbhai, Patel, Harsh , Deshmukh, Abhishek , Bhakta, Shyam , Thakkar, Samarthkumar

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 12, 2022 | Volume: 15 | Issue: Suppl_1 | Pages: No page available

10.1161/circoutcomes.15.suppl_1.271 Get It

Background: Different arrhythmias have been reported in patients with COVID-19 due to the complication of the disease, and medications used in the management of COVID-19. Remdesivir was approved by FDA for the management of COVID-19 patients in October 2020. There are several case reports suggesting remdesivir causing bradyarrhythmia in COVID-19 patients. Objective: To increase the knowledge and awareness among healthcare professions (HCPs) about the risk of arrhythmias associated with the use of remdesivir. Methods: We used the FDA Adverse Events Reporting System (FAERS) database to find bradyarrhythmia as a reported adverse event (AE) due to remdesivir until October,2021. Total 6,504 events were reported, out of which 5,996 (92.2%) were reported by HCPs. These AEs were included and further analyzed. Results: Out of 5,996 AEs reported with remdesivir, total 537 (9.0%) events were bradyarrhythmia. There were 74 (1.27%) events reported for atrial fibrillation, and 24 (0.04%) for ventricular tachycardia attributed to the use of remdesivir. Reported events of bradyarrhythmia were further divided and analyzed into men vs women, and different age groups of years 18-64, 65-85, &gt;85. Total events of bradyarrhythmia among men (238, 6.5%) vs women (141, 6.4%) were not significantly different. Among all the age groups, more events were reported in younger women in the age group of 18-64 (12.3%) vs 65-85 (7.9%) vs &gt;85 (6.9%). Conclusion: Multiple studies have shown COVID-19 associated tachyarrhythmias, likely secondary to the myocardial damage due to hypoxia. Few studies have also suggested bradyarrhythmias in these patients. Our analysis of the FAERS database also showed many reported AEs of bradyarrhythmia attributed to the use of remdesivir. Postulated mechanisms include; medication side effects, damage to the SA node as a complication of the COVID-19 disease process, and electrolyte imbalance due to the renal failure. Close surveillance of these patients with early diagnosis can lead to prompt discontinuation of the medication, which can further decrease the mortality related to bradyarrhythmias. Further studies are required to identify the at-risk population and to better understand the risk of bradyarrhythmia associated with remdesivir.
Abstract 264: Tachyarrhythmias Associated With Sacubitril-valsartan - A Pharmacovigilance Analysis:
Pandya, Krutarth K , Moussa, Zahir, Shah, Parth Rajeshbhai, Patel, Harsh , Bhakta, Shyam , Deshmukh, Abhishek , Thakkar, Samarthkumar

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 12, 2022 | Volume: 15 | Issue: Suppl_1 | Pages: No page available

10.1161/circoutcomes.15.suppl_1.264 Get It

Background: Sacubitril-valsartan is a combination of a neprilysin inhibitor and an angiotensin II receptor blocker respectively. Sacubitril-valsartan has become a standard of care in the treatment of patients with Congestive Heart Failure (CHF) with reduced EF. During its clinical trials and upon review of U.S. Food and Drug Administration (FDA) approval, sacubitril-valsartan exhibited a side effect profile including hyperkalemia, hypotension, renal dysfunction, and angioedema. Recently, sacubitril-valsartan was also approved for the treatment of CHF patients with preserved EF. Objective: In view of new indications and increased usage, it is important to establish the updated safety profile of sacubitril-valsartan in the general population since the PARADIGM-HF trial. Methods: We explored reported Adverse Events (AEs) of sacubitril-valsartan using the FDA Adverse Event Reporting System. A total of 57,958 AEs were reported until August 2021. Total of 16,658 (28.7%) AEs were reported by HCPs, which were further analyzed. AEs were analyzed in men (56.7%) vs women (25.3%), and also in 3 age groups of 18-64, 65-85, >85. Results: Out of 16,658 AEs, the most frequently reported AE was hypotension (17.2%). Other commonly reported AEs were renal dysfunction (14.3%), allergic reactions including angioedema (10.8%), GI distress (8.8%), tachyarrhythmias (5.8%), hyperkalemia (4.5%), and cough (3.0%). Out of 16,658 AEs, 11,631 (69%) were deemed serious and 4,422 (26.5%) resulted in hospitalization. Deaths were attributed to 3,909 serious AEs (23.5%). In the age group of 18-64, events of atrial fibrillation were less among women compared to men (1% vs 3%), while total events of ventricular tachycardia were noted more among men compared to women (2% vs 0.5%). Conclusion: Most of the reported AEs were consistent with the observed AEs from PARADIGM-HF except for tachyarrhythmia. There are few reports documenting arrhythmias followed by the use of sacubitril-valsartan, however, the clear mechanism is unknown. Despite the wide use of sacubitril-valsartan, there is currently limited data on the safety profile. In future with the increasing use, further randomized controlled trials (RCTs) are needed to better understand the safety profile of the medication.
Response to: Outcomes of Micropulse Transscleral Cyclophotocoagulation in Eyes With Good Central Vision
Varikuti, Venkata N.V., Rai, Oshin, Chaves, Ariel , Miranda, Alex, Lim, Boon-Ang, Dorairaj, Syril , Sieminski, Sandra , Dorairaj, Syril K., Shah, Parth Arvind

Mayo Clinic

Journal of Glaucoma | March 18, 2020 | Volume: 29 | Issue: 6 | Pages: e53-e54

10.1097/ijg.0000000000001490 | PMID 32187078 Get It

Response to: Outcomes of Micropulse Transscleral Cyclophotocoagulation in Eyes With Good Central Vision
Sieminski, Sandra , Varikuti, Venkata N.V., Rai, Oshin, Chaves, Ariel , Miranda, Alex, Lim, Boon-Ang, Dorairaj, Syril , Dorairaj, Syril K., Shah, Parth Arvind

Mayo Clinic

Journal of Glaucoma | January 8, 2020 | Volume: 29 | Issue: 3 | Pages: e16-e17

10.1097/ijg.0000000000001437 | PMID 31913223 Get It

Outcomes of Micropulse Transscleral Cyclophotocoagulation in Eyes With Good Central Vision
Varikuti, Venkata N.V., Rai, Oshin, Chaves, Ariel , Miranda, Alex, Lim, B.J., Dorairaj, Syril , Sieminski, Sandra , Chaves, Ariel C, Lim, Boon-Ang, Dorairaj, Syril K., Shah, Parth Arvind , Lim, Boon-Ang

Mayo Clinic

Journal of Glaucoma | August 5, 2019 | Volume: 28 | Issue: 10 | Pages: 901-905

10.1097/ijg.0000000000001339 | PMID 31385915 Get It

Precis: This study is the first to report micropulse transscleral cyclophotocoagulation (MP-TSCPC) use in only good vision patients. MP-TSCPC significantly reduced intraocular pressure (IOP) and glaucoma medication use without any significant reduction in visual acuity at every postoperative follow-up point. Purpose: To evaluate outcomes of MP-TSCPC in eyes with baseline best-corrected visual acuity (BCVA) of ≥20/60. Methods: A retrospective review of patients who underwent MP-TSCPC at Mayo Clinic and Ross Eye Institute from July 2016 to August 2017 with BCVA of ≥20/60, and a minimum of 3 months follow-up. Results: A total of 61 eyes of 46 patients (68.80±17.12 y) underwent MP-TSCPC with a mean follow-up of 10.2±3.1 months. Mean IOP and mean number of glaucoma medications used were significantly reduced from baseline at every follow-up time point ( P <0.0001). At month 12, mean IOP was reduced 40.2% from baseline with 85.4% of the patients having an IOP reduction of ≥20%, and mean glaucoma medication use reduced by 0.82±0.53 with 79.6% of the patients having a reduction of ≥1 medication. There was no significant reduction in BCVA from baseline at any follow-up point ( P >0.05), except for 10 eyes with a vision loss of ≥2 lines and 5 out of 10 eyes had cataract progression. The probability of complete success (IOP range, 6 to 21 mm Hg or ≥20% IOP reduction; BCVA loss ≤2 lines, no reoperation for glaucoma) was 74.14%, 83.61%, 84.21%, and 75.0% at months 1, 3, 6, 12, respectively. The probability of qualified success (above criteria for IOP, no reoperation and BCVA loss >2 lines) was 81.03%, 91.80%, 94.74%, and 93.75% at months 1, 3, 6, 12, respectively. Conclusions: MP-TSCPC should be considered earlier in the management of glaucoma and can possibly be offered as an alternative to incisional glaucoma surgeries.
Predictors of incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors
Moustafa, Sherif, Ho, Thai H. , Shah, Parth , Murphy, Katie , Nelluri, B.K., Lee, Howard , Wilansky, Susan , Mookadam, Farouk , Nelluri, Bhargava K, Ho, Thai

Mayo Clinic

Journal of Clinical Ultrasound | February 15, 2016 | Volume: 44 | Issue: 4 | Pages: 221-230

10.1002/jcu.22333 | PMID 26875513 Get It

ABSTRACTPurposeWe aimed to explore the hypothesis that early subclinical cardiac chamber dysfunction secondary to tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma could be signaled by abnormal cardiac mechanics demonstrated by velocity vector imaging.MethodsEchocardiographic images were acquired from the apical views in 23 metastatic renal cell carcinoma patients. All patients had baseline and at least a 3‐month follow‐up echocardiogram after receiving TKI therapy. Subendocardial borders of all the cardiac chambers were traced to obtain volumetric and deformation indices.ResultsMean age was 67 ± 9 years with 92% men. The right ventricle peak systolic global longitudinal strain (GLɛ) and strain rate were significantly lower after TKIs (−23.49 ± 5.1 versus −19.81 ± 5.5, p = 0.002 and −1.52 ± 0.52 versus −1.24 ± 0.35 p = 0.02, respectively). LV GLɛ was not statistically different. Volumetric and deformation indices showed a minimal decrease of the right atrium reservoir and conduit functions, and no significant changes of left atrial function.ConclusionsThe right heart exhibited greater strain changes than the left heart after TKI treatment. The implications of these findings and their potential significance warrant further work. © 2016 Wiley Periodicals, Inc. J Clin Ultrasound 44:221–230, 2016
Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Patients
Moustafa, Sherif, Murphy, Katie , Nelluri, B.K., Northfelt, Donald W. , Shah, Parth , Lee, Howard , Wilansky, Susan , Naqvi, Tasneem Z. , Meyer, Susan M. , Mookadam, Farouk , Nelluri, Bhargava K, Northfelt, Donald, Meyer, Susan, Mookadam, Farouk

Mayo Clinic

Echocardiography | October 24, 2015 | Volume: 33 | Issue: 3 | Pages: 406-415

10.1111/echo.13087 | PMID 26498324 Get It

BackgroundTrastuzumab has substantially improved overall survival and reduced the risk of disease recurrence in patients with human epidermal growth factor receptor type II (HER‐II)–positive breast cancer. However, this benefit may be at the increased risk of cardiotoxicity. We aimed to explore the early subclinical left and right ventricular as well as atrial dysfunction, in trastuzumab‐treated patients with HER‐II–positive breast cancer, using velocity vector imaging.MethodsEchocardiography images were acquired in 50 patients with HER‐II–positive breast cancer undergoing trastuzumab therapy. All patients had baseline and 3–6 months and 12–15 months of follow‐up echocardiograms after initiation of trastuzumab therapy. Subendocardial borders of all the cardiac chambers were traced from the apical views to obtain volumetric and deformation indices.ResultsMean age was 60 ± 13 years. Left ventricular (LV) ejection fraction as well as conventional indices of right ventricular (RV) function did not change with trastuzumab. The RV peak systolic global longitudinal strain (GLε) significantly decreased (−24.53 ± 6.03 vs. −21.28 ± 5.11 vs. −21.84 ± 5.15, baseline vs. first and second follow‐ups, P = 0.01). LV peak systolic GLε was reduced by 1.19 at early follow‐up (P < 0.05). Left atrial reservoir and booster pump functions as well as right atrial reservoir function were reduced through follow‐up as well.ConclusionsThe RV exhibited greater change in strain after trastuzumab treatment when compared to the LV. Atria function was reduced by trastuzumab as well. The repercussion of these findings and their potential implication will warrant further study.
Covert tricuspid valve rupture secondary to blunt chest trauma
Moustafa, Sherif, Ejaz, Nauman, Shah, Parth

Mayo Clinic

Asian Cardiovascular and Thoracic Annals | March 11, 2015 | Volume: 24 | Issue: 6 | Pages: 607-608

10.1177/0218492315575946 | PMID 25762079 Get It